Matinas Biopharma Holdings Inc (MTNB)

[middle man]

Lookin for a re-entry myself things should start cooling off and headin north soon

[dhbuzz]

STILL HOLDING...

[vdt]

No RS, yep, ready to rock!

[middle man]

Looks pretty bad here at mtnb end of day dump fest

[dhbuzz]

READY TO ROCK!

[Raffis]

Watch video (& see 4:37):

[Raffis]

About the Reverse Split: “ - Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022.”
https://www.globenewswire.com/news-release/2020/12/07/2140379/0/en/Matinas-BioPharma-Files-Preliminary-Proxy-for-Special-Meeting-of-Stockholders.html

MTNB inside buyers will not vote to split their inside-purchased stock, without guaranteeing that their shares will not be affected. There is something very peculiar about this scenario. And it looks like MTNB is in on it. Why would MTNB have a special meeting-vote to split the stock after their inside buys? Did anyone hear anything about the meeting and the votes?

Or is it that the insiders plan to sell their shares before and for how much? Be careful. There’s something strange going on here. And since they are talking reverse split, with Market Maker manipulation, says the company doesn’t look good. So they need the Market Maker to play LIQUIDITY games at 6:05 AM for a $2.35 spike that’s at $1.25 a day later and not the same day. The $2.35 was Market Maker Money - - it had to be. So how can a split be needed, if MAT9001 and LNC are as good as they say. LNC, by concept, would be the first drug delivery system to cross the Blood Brain Barrier. LNC IS A DISRUPTIVE BREAK THROUGH. LNC CAN PUT PHARMACEUTICAL COMPANIES OUT OF BUSINESS. I BELIEVE THAT MTNB IS IN SOME SORT OF TROUBLE, BECAUSE OF LNC. AND I ALSO STRONGLY BELIEVE THAT BIG PHARMA IS BEHIND THIS. LNC WAS REVIEWED BY MULTIPLE BIG PHARMA COMPANIES. IF BIG PHARMA IS STILL CHECKING LNC OUT, THEN MTNB IS BEING THREATENED OR BLACKMAILED. I CAN ASSURE YOU THAT REMDISIVIR DOES NOT NEED LNC DELIVERY. REMDISIVIR WAS ADMINISTERED WITHOUT LNC. SOMETHING IS GOING ON HERE. I BELIEVE THAT MTNB IS IN SOME SORT OF TROUBLE WITH BIG PHARMA GOONS.

[Raffis]

And watch this video:

Market Makers provide liquidity. They do this by trying to find the best ways of taking your money, or trying to make you lose it, whether you sell or buy. The Market Maker will dump the stock on the spike that you rode up, and by doing this will try to either get you to panic sell or lock you into the position that he will gamble on, hoping that you sell. You and I need to think about this carefully. I have made and lost money. There is a way to not lose any more. It doesn’t have anything to do with patience for a long position. It has to do with patience in accumulating money. The stock market has shifted the Market Makers to use different strategies. So now you need to understand the shifts and adjust accordingly.

Watch the stocks, now. Watch the “new” Reddit psychological “retail investor” hype. At some point you will see through the deception.

But I will tell you right here and now, they are all Market Maker Moves, behind the scenes. Everything closed during the COVID Pandemic. Things are still closed and affected. This will not change, ever. We wear masks, now. The CDC knew about Coronavirus in 1960. Look here: https://www.cdc.gov/coronavirus/types.html “Human coronaviruses were first identified in the mid-1960s. The seven coronaviruses that can infect people are:.....”

And we were open the whole time, without masks from 1960. Think about this and how many people were infected with the corona virus, since 1960 and no one said a word, including the CDC. A Market Maker will spike a stock at 6:05 AM, because no one can trade it. The Market Maker knew this. And the Market Maker controlled it. It was a trick to get people in. There is a way to never lose money in the stock market and always make money in the stock market. Observe for now. And be impartial, not emotional.

The Stock Market (Makers) never closed. This is the truth.

[Raffis]

Watch this video:

MTNB spiked 6:05 AM, Tuesday. Then the spike returned to the breakout level. That was a Market Maker messing around with retail traders’ heads. Because the Market Maker was using the time frame as a strategy to attract suckers into the movement for panic selling. And the market maker added a few more strategies to scare traders into selling on STOCKTWITS with reverse split suggestions. The stock dropped down to .86 after the spike and never passed 1.10, until, Wednesday. Think about this Market Maker and the manipulation that was conducted.

[blh28]

Thanks Raffis. The insider purchases at the beginning of 2021 are very impressive. I'm in.

[The Lawman]

Perhaps it's just me, but I will take the word of Dr. Kastelein, perhaps the world's foremost authority on lipid cardiology, over paid bashers and shorts.

According to Dr. Kastelein, the most significant factor lipid factor in reducing cardiac events (CE) is the level of EPA in the blood.

On this count, MAT 9001 again handily bested Vascepa for the second time.

Moreover, in the per protocol (PP) group, MAT 9001 showed clinically significant improvement over Vascepa in reducing triglycerides, along with many other lipid markers. This is especially significant as the PP group consists of those patients who actually took the drug as prescribed rather than those who are less careful about doing so.

Presumably, if a patient does to the trouble of getting a prescription for MAT 9001, he/she would take it as prescribed. If so, he/she will have much higher EPA blood levels, and much lower triglycerides than if he/she had taken Vascepa.

More significantly, given the higher level of EPA in the blood, it stands to reason those patients taking MAT 9001 will have a significantly greater reduction in cardiac events than the 25% reduction in CE shown for those patients taking Vascepa.

My opinions, of course, but they would seem to be supported by the trials to date, along with the opinions of prominent scientists and cardiologists, including Dr. Kastelein.

[Raffis]

Look at the inside buys: https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021##document-5920-0001493152-21-000130

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021##document-5919-0001493152-21-000132

https://www.matinasbiopharma.com/investors/sec-filings/section-16-filings?form_type=&year=2021

[Raffis]

BZ: UPDATE: “Matinas BioPharma Announces 'LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA (eicosapentaenoic acid) change from baseline over Vascepa”

[Raffis]

It was not a clinical trial result. It was only head to head. The results were super. But many don’t understand them, yet. This is why price went up. Shorts brought price down. This can still fly.

[Raffis]

Look at fourth slide from bottom: https://www.sec.gov/Archives/edgar/data/1582554/000149315221000992/ex99-1.htm

[blh28]

If the results were that good, why the drop in SP? I'm confused.

[Raffis]

MAT9001 & Vascepa are studied “as adjuncts to statins.” They we’re not administered alone. MAT9001 blew VASCEPA away - - “as an adjunct to statin therapy.” Therefore MAT9001 has higher efficacy than VASCEPA alone and with Statins. VASCEPA is weaker and less effective.

[Raffis]

READ: https://pubmed.ncbi.nlm.nih.gov/28391875/

Background: Long-chain omega-3 fatty acid concentrate pharmaceuticals are used in the United States for treatment of severe hypertriglyceridemia (≥500 mg/dL) and are under investigation as adjuncts to statins for lowering cardiovascular risk in patients with high triglycerides (TGs; 200-499 mg/dL).

Objective: To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid, in 42 men and women with fasting TG 200 to 400 mg/dL.

Methods: In this open-label, crossover trial, subjects received MAT9001 and EPA ethyl esters (EPA-EE) in random order. They were housed in a clinical research unit for 2 14-day treatment periods, separated by a ≥35-day washout. Lipoprotein lipids, apolipoproteins (Apos) and proprotein convertase subtilisin kexin type 9 levels were measured before and at the end of each treatment period.

Results: MAT9001, compared with EPA-EE, resulted in significantly (P < .05) larger reductions from pretreatment levels for TG (-33.2% vs -10.5%), total cholesterol (-9.0% vs -6.2%), non-high-density lipoprotein cholesterol (-8.8% vs -4.6%), very low-density lipoprotein cholesterol (-32.5% vs -8.1%), Apo C3 (-25.5% vs -5.0%), and proprotein convertase subtilisin kexin type 9 (-12.3% vs +8.8%). MAT9001 also produced a significantly (P = .003) larger reduction in Apo A1 (-15.3% vs -10.2%), but responses for high-density lipoprotein cholesterol (-11.3% vs -11.1%), low-density lipoprotein cholesterol (-2.4% vs -4.3%), and Apo B (-3.8% vs -0.7%), respectively, were not significantly different relative to EPA-EE.

Conclusions: MAT9001 produced significantly larger reductions than EPA-EE in several lipoprotein-related variables that would be expected to favorably alter cardiovascular disease risk in men and women with hypertriglyceridemia.

Trial registration: ClinicalTrials.gov NCT02310022.

Keywords: Docosapentaenoic acid; Eicosapentaenoic acid; Hypertriglyceridemia; Omega-3 fatty acids; Proprotein convertase subtilisin kexin type 9; Triglycerides.

[AnotherInvestor]

People sold on the great news that came out. Interesting

[Cosa]

Pennant forming, could break either way. I'm watching carefully.

[XenaLives]

Informative Excerpt:

A UNIQUE APPROACH: COCHLEATE LIPID-CRYSTAL NANOPARTICLE- TARGETED DRUG DELIVERY TECHNOLOGY

Unique approaches to treating these diseases that may provide effective antifungal treatment while minimizing severe toxicities include the development of such agents in unique formulations. Matinas BioPharma, a clinical-stage biopharmaceutical company focused on identifying and developing anti-fungal and anti-bacterial therapeutics for life-threatening infections, is currently testing its most advanced product, MAT2203, an orally administered, encochleated formulation of the broad-spectrum antifungal medication amphotericin B (AmB) for the treatment of serious and life-threatening fungal infections.

https://drug-dev.com/delivery-platform-encochleated-drug-formulations-enhancing-efficacy-minimizing-toxicity/

[The Lawman]

Lypdiso is the brand name for MAT 9001, that is now in a second head to head trial vs. Vascepa, with topline results to be announced in 1Q 21. I expect such results to again show that MAT 9001 is far superior to Vascepra in lowering triglycerides, PCSK9, and various other lipid markers.

Also in the MTNB pipeline are (1) MAT 2203 (LNC version of amphotericin b), which is now in a Phase 2 trial for cryptococcal meningitis, fully funded and sponsored by the NIH, and (2) MAT 2205 (LNC version of amikacin), which has funding for research from the Cystic Fibrosis Foundation.

Of course, the LNC platform can potentially make many more effective, but highly toxic, drugs, safe and effective, which is why five big pharmaceutical companies are now in collaborations with MTNB to encochleate their drugs.

[ClayTrader]

* * $MTNB Video Chart 01-04-2021 * *

Link to Video - click here to watch the technical chart video

[vdt]

MTNB get much attention! Still I am cautious of Reverse Split coming in January !
Thanks for your info. Meanwhile, enjoy a good ride up, end of year.
Happy New Year 2021 everyone. Good Luck.

[ClayTrader]

* * $MTNB Video Chart 12-29-2020 * *

Link to Video - click here to watch the technical chart video

[vdt]

Nice jump today, 24%, but I am nervous about the REVERSE SPLIT
that they want for MTNB, announced after January meeting.

[The Lawman]

$4 price target by BTIG's 5 star analyst, Robert Hazlett, helps, but it is old news.

What is more important are the reasons given by Hazlett for his $4 price target:

1. Ongoing LNC trials funded by the NIH and CF Foundation;

2. Soon to be announced results from a second head to head trial of MAT 9001 vs. Vascepa, with results expected to strongly favor MAT 9001; and

3. Collaborations with 5 big pharmaceutical companies, any one of which could choose to purchase MTNB at a huge premium for what would be a pittance for any of these companies.

[dhbuzz]

Pretty nice buys going through.
Now clear out the d traders.
Lets GO!

[dhbuzz]

[dhbuzz]

Matinas put out a PR DEC.7.Glad you are not in charge of my holdings.......


jus' sayin'

https://ih.advfn.com/stock-market/AMEX/matinas-biopharma-MTNB/stock-news/83841460/proxy-statement-notice-of-shareholders-meeting-p

[The Lawman]

Short term catalysts abound from top line results for the MAT 9001's second head to head trial vs. Vascepa in 1Q 21, to the DMSC approval for next cohort progression for the MAT 2203 (LNC version of amphotericin b) Phase 2 trial for cryptococcal meningitis in 2Q 21. In addition, the MF Foundation has funded a trial for MAT 2501 (LNC version of amikacin) that should commence soon. Five big pharmaceutical companies, who have entered into collaborations with MTNB show confidence in the company, and its LNC platform.

As for funds, the company has cash on hand sufficient to fund operations through mid-2023. As such, no raise will be needed before major milestones are achieved.

[Gettys_Burg]

Ah, so now we know why the stock has been plummeting the past week. Just received my proxy notice for vote on a reverse split yesterday, dated Dec.17. Insiders had the heads up and we're left holding the bag. This will fall back to the .75-.80 channel this week. Dang, knew I should've sold when we spiked to $1.25!

[dhbuzz]

NO doubt ,these upcoming days for results of Mtinas MAT 9001 are huge.

Merry Christmas to all*********

[The Lawman]

Results from the second head to head trial of MAT 9001 vs Vascepa will be announced in 1Q 2021. If, as expected, MAT 9001 again proves to be much more effective than Vascepa in lowering triglycerides, and PCSK9 levels, that alone should boost the price at least 3X.

Then there are the ongoing trials for the LNC formulations of amphotericin b and amikacin, that are being funded by the NIH and CF Foundation, respectively, either of which, if successful, could catapult the SP of the stock.

And of course, MTNB is in collaboration with numerous BP companies including Gilead, Sanofi, and Regeneron, each of which has asked MTNB to encochleate their drugs to make them safer and orally available.

If even one of these BP trials proves to be successful, MTNB could be acquired at a huge premium to its current SP.

Management comes from BP, including its chairman, Herb Conrad, who was president of Roche, and know how to get drugs approved, and a company sold.

[dhbuzz]

Play ball!

[The Lawman]

Correction of last post:

Whatever the reason for the EOY drop, catalysts abound in the coming 6 months including topline results for MAT 9001's head-to-head trial vs. Vascepa, and DSMC authorization to dose the next cohort of patients in the NIH funded MAT 2203 trial for the LNC version of amphotericin b.

The muscular dystrophy foundation funded study of MAT 2501--the LNC version of amikacin--and results from numerous collaborations with BP, including Gilead, Sanofi, and Regeneron, also loom on the horizon.

Note that Matinas' market cap is only a fraction of Amarin, whose primary product, Vascepa, I expect will soon be shown to be far less effective than MAT 9001 in reducing triglycerides.

Also note that Matinas' market cap is only a fraction of that of Insmed whose primary product is an inhalable version of amikacin I expect will soon be shown to be more toxic, and less effective, than MAT 2202, which is an oral LNC version of this drug.

Led by a strong management team, I fully expect Matinas to trade at many multiples of its current SP in 2021.

LM

[The Lawman]

Whatever the reason for the EOY drop, catalysts abound in the coming 6 months including topline results for MAT 9001's head-to-head trial vs. Vascepa, and DSMC authorization to dose the next cohort of patients in the NIH funded MAT 2203 trial for the LNC version of amphotericin b.

The muscular dystrophy foundation funded study of MAT 2501--the LNC version of amikacin--and results from numerous collaborations with BP, including Gilead, Sanofi, and Regeneron, also loom on the horizon.

Note that Matinas' market cap is only a fraction of Amarin, whose primary product, Vascepa, I expect will soon be shown to be far less effective than MAT 9001 in reducing triglycerides.

Also note that Matinas' market cap is only a fraction of that of Insmed whose primary product is an inhalable version of amphotericin b I expect will soon be shown to be more toxic, and less effective, than MAT 2202, which is an oral LNC version of this drug.

Led by a strong management team, I fully expect Matinas to trade at many multiples of its current SP in 2021.

LM

[dhbuzz]

Another BINGO!...https://www.globenewswire.com/news-release/2020/12/01/2137305/0/en/Matinas-BioPharma-Appoints-Hui-Liu-Ph-D-M-B-A-as-Chief-Technology-Officer.html

[LOQUITO]

Yeah, what happened??

[akocaman]

what happened?

[dhbuzz]

BINGO!!!

[dhbuzz]

HOLD ON !!!!

[dhbuzz]

Added @ .85

[dhbuzz]

The garden is REALLY perking up.

[dhbuzz]

Added@.88

[dhbuzz]

Added @ .88

[dhbuzz]

Looking good.

[dhbuzz]

https://www.bing.com/videos/search?q=train+leaving+statio&docid=608004766164517271&mid=8A4AE674AB548147D92E8A4AE674AB548147D92E&view=detail&FORM=VIRE

[dhbuzz]

Added @ .75*****GLTA

[dhbuzz]

Added @.77 *****GLTA